Program
vaccination of GC3114B
A development code.
Its studies are mostly in Influenza, Human, led by GC Biopharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GC Biopharma | 11 open or running | phase 3since Oct 11, 2026 | Oct 11, 2026 | Mar 2028phase 3 · NCT07883928 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2026First study: phase 3 study in Influenza, HumanFirst studyNCT07883928 · 1,806 planned · South Korea
Ahead
- Mar 2028Primary completion: phase 3 study in Influenza, HumanNCT07883928
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07883928Influenza, Human · South Korea | 3 | Recruiting | Mar 2028 | 1,806 |
How it is read
Names in the registry
- “vaccination of GC3114B”, 1 entry
Codes read as this program: GC3114B.
Conditions, from the studies’ own filings
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.